Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTFields + temozolomide
- Development stage
- Unknown
- Lead developer
- NovoCure
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Topical
01
Overview
TTFields + temozolomide is a combination therapy used primarily for the treatment of newly diagnosed glioblastoma. Tumor Treating Fields (TTFields) are low-intensity, alternating electric fields delivered non-invasively to the scalp via transducer arrays (commercially known as Optune). These fields disrupt mitosis and inhibit tumor cell proliferation by interfering with microtubule assembly and other cellular processes essential for cancer cell division. Temozolomide is an oral alkylating agent that induces DNA damage in tumor cells, leading to apoptosis. The combination has demonstrated synergistic effects in preclinical and clinical studies, resulting in improved progression-free survival (PFS) and overall survival (OS) compared to temozolomide alone. This regimen is approved as first-line maintenance therapy following chemoradiation in newly diagnosed glioblastoma patients[2][3][4][5].
- Brand names
- Optune + temozolomide
- Other names
- Tumor Treating Fields + temozolomideTTFields plus temozolomideTumor-Treating Fields plus temozolomideOptune with temozolomide
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on TTFields + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTFields + temozolomide.